Letters Glucosamine and osteoarthritis

Effect size is encouraging

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6328 (Published 09 November 2010) Cite this as: BMJ 2010;341:c6328
  1. Jean-Pierre Pelletier, professor of medicine and head1,
  2. Marc C Hochberg, professor of medicine and head2,
  3. Patrick du Souich, professor and director3,
  4. André Kahan, professor of rheumatology and head4,
  5. Beat A Michel, professor and chair5
  1. 1Division of Rheumatology, University of Montreal, Canada
  2. 2Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, USA
  3. 3Department of Pharmacology, Faculty of Medicine, University of Montreal, Canada
  4. 4Paris Descartes University, Faculty of Medicine, and Department of Rheumatology A, Cochin Hospital, AP-HP, France
  5. 5Department of Rheumatology and Institute for Physical Medicine, University Hospital Zurich, Switzerland
  1. dr{at}jppelletier.ca

The results and interpretation of the meta-analysis by Wandel and colleagues of the effects of glucosamine and chondroitin on osteoarthritis depend on the trials analysed and the thresholds defined as clinically relevant.1

The criteria for the selection of trials is questionable; the European Medicines Agency recommends evaluating the analgesic effect of slow acting drugs for osteoarthritis after at least six months of treatment, and the structural effect after two years. …

View Full Text

Log in

Log in through your institution


* For online subscription